Valuation: Colinz Laboratories Limited

Market Cap 19Cr 19.23L 17.08L 15.93L 14.52L 27.4L 27.65L 1.93Cr 74.83L 9.44Cr 72.18L 70.62L 30Cr P/E 2025
36.8x
P/E 2026 21.8x
Enterprise Value 10Cr 10.77L 10L 9L 8L 15.35L 15.5L 1.08Cr 41.94L 5.29Cr 40.45L 39.57L 17Cr EV / Sales 2025
2.04x
EV / Sales 2026 0.5x
Free-Float
31.44%
Yield 2025 *
-
Yield 2026 -
20/08 Annjana Dugar, Likhitta Dugar and Antariksh Dugar completed the acquisition of an additional 0.000238% stake in Colinz Laboratories Limited for INR 324. CI
30/07 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million. CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
25/05 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
29/04 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
24/01 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
17/01 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
27/11 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
08/11 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
03/11 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/25/31 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/25/21 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
1 day-4.16%
1 week-2.00%
Current month-4.16%
1 month+0.96%
3 months-14.46%
6 months+59.78%
Current year+37.05%
1 week 71.1
Extreme 71.1
78.7
1 month 68.1
Extreme 68.1
78.7
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 18.05
Extreme 18.05
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 20/05/2019
Compliance Officer - 01/12/2025
Director TitleAgeSince
Director/Board Member 74 26/11/1990
Director/Board Member 34 08/08/2024
Director/Board Member 76 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.16%-2.00%+69.79%+79.71% 19.23L
-0.61%-3.30%+38.46%+112.77% 1,02500Cr
-1.02%-5.41%+37.61%+64.39% 62TCr
+1.11%-0.87%+7.55%+76.32% 46TCr
+0.34%-2.49%+60.10%+40.17% 35TCr
-0.95%-4.87%+22.46%+38.03% 34TCr
-1.46%-2.20%+11.84%+23.94% 27TCr
-1.35%-4.27%-4.55%+6.92% 25TCr
-1.04%-0.74%+35.02%+49.96% 22TCr
-1.87%-3.31%+30.22%+93.14% 18TCr
Average -0.72%-1.90%+30.85%+58.53% 37.18TCr
Weighted average by Cap. -0.12%-2.11%+29.72%+68.31%

Financials

2025 2026
Net sales 6.53Cr 7L 6L 6L 5L 10L 10L 68.07L 26.38L 3.33Cr 25.45L 24.9L 11Cr 6.14Cr 6L 6L 5L 5L 9L 9L 63.99L 24.8L 3.13Cr 23.92L 23.4L 10Cr
Net income 49.66L 51.57T 45.82T 42.72T 38.95T 73.48T 74.17T 5L 2L 25.32L 2L 2L 81.43L 51.45L 53.43T 47.47T 44.26T 40.35T 76.13T 76.84T 5L 2L 26.24L 2L 2L 84.36L
Net Debt -4.91Cr -5L -5L -4L -4L -7L -7L -51.2L -19.84L -2.5Cr -19.14L -18.72L -8.05Cr -8.14Cr -8L -8L -7L -6L -12.04L -12.16L -84.88L -32.9L -4.15Cr -31.73L -31.04L -13Cr
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
62
Date Price Change Volume
01/26/01 ₹73.50 -4.16% 2,711
30/26/30 ₹76.69 +2.31% 3,879
29/26/29 ₹74.96 +0.35% 1,319
28/26/28 ₹74.70 -1.97% 741
25/26/25 ₹76.20 +1.60% 263
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock